<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01006499</url>
  </required_header>
  <id_info>
    <org_study_id>1-akdag</org_study_id>
    <nct_id>NCT01006499</nct_id>
  </id_info>
  <brief_title>Role of 'Pentoxifylline and or IgM Enriched Intravenous Immunoglobulin in the Treatment of Neonatal Sepsis'</brief_title>
  <official_title>Phase 4 Study of Role of 'Pentoxifylline and or IgM Enriched Intravenous Immunoglobulin in the Treatment of Neonatal Sepsis'</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zekai Tahir Burak Women's Health Research and Education Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zekai Tahir Burak Women's Health Research and Education Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim is to investigate whether adjuvant Pentoxifylline , IgM enriched IVIG
      or Pentoxifylline plus IgM-enriched IVIG reduced mortality from Neonatal sepsis.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2009</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">October 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>patient characteristics all cause mortality</measure>
    <time_frame>two years</time_frame>
    <description>Does adjuvant Pentoxifylline or Pentoxifylline plus IgM-enriched IVIG reduce mortality from Neonatal sepsis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurodevelopmental morbidity secondary to sepsis at the age of 18 months Difference in biomarker levels</measure>
    <time_frame>two years</time_frame>
    <description>Assess the effectiveness of Pentoxifylline or Pentoxifylline plus IgM enriched IVIG in reducing neuro-developmental morbidity secondary to sepsis at the age of 18 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect the production of pro-inflammatory bio-markers.</measure>
    <time_frame>two years</time_frame>
    <description>Whether Pentoxifylline or Pentoxifylline plus IgM enriched IVIG reduces the production of pro-inflammatory bio-markers</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Sepsis of the Newborn</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Receiving standard treatment plus placebo (5 mls/Kg of normal saline intravenously given over 4 hours).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentoxifylline group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment plus 6 mg/Kg of Pentoxifylline intravenously (given over 4 hours) daily for three days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentaglobin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentoxifylline plus Pentaglobin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard treatment plus 6 mg/Kg of Pentoxifylline plus 250 mg/Kg of Pentaglobin intravenously (given over 4 hours) daily for three days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline, pentaglobin</intervention_name>
    <description>Pentaglobin 250mg/kg/d over 4 hour for three days Pentoxyfilline 6mg/kg/h over 4 hour for three days Pentaglobin 250mg/kg/d over 4 hour for three days+Pentoxyfilline 6mg/kg/h over 4 hour for three days Placebo (normal saline 5ml/kg over 4 hour for three days</description>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_label>Pentoxifylline group</arm_group_label>
    <arm_group_label>Pentaglobin group</arm_group_label>
    <arm_group_label>Pentoxifylline plus Pentaglobin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria::

          -  All infants thought/diagnosed to have late or early onset sepsis.

        Exclusion Criteria:

          -  Pentoxifylline or Pentaglobin has already been given

          -  Pentoxifylline or Pentaglobin is thought to be needed or contra-indicated

          -  Major congenital anomaly

          -  Intraventricular hemorrhage (Grade 3 veya 4)

          -  Congenital infections

          -  Inborn errors of metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>90 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zekai Tahir Burak</name>
      <address>
        <city>Ankara</city>
        <zip>06120</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2009</study_first_submitted>
  <study_first_submitted_qc>November 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2009</study_first_posted>
  <last_update_submitted>March 10, 2011</last_update_submitted>
  <last_update_submitted_qc>March 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Arzu AkdaÄŸ</name_title>
    <organization>ZTB</organization>
  </responsible_party>
  <keyword>neonatal sepsis</keyword>
  <keyword>pentoxyfilline</keyword>
  <keyword>pentaglobin</keyword>
  <keyword>biomarker</keyword>
  <keyword>To reduce mortality in neonatal sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Neonatal Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 2, 2013</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>August 25, 2013</submitted>
    <returned>October 30, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

